ArticleBiologics : targets & therapy2016
Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.
Article in Biologics : targets & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Acyclovir Combined with Naloxone in the Treatment of Viral Encephalitis: A Meta-Analysis.Journal of healthcare engineering · 2022Pooled it
- [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].Zeitschrift fur Rheumatologie · 2020Pooled it
- Evaluation of the Effect of IL-1 Antagonists on Pituitary Function.International journal of endocrinology · 2026Article
- Syndrome of undifferentiated recurrent fever (SURF): a multicenter real-world experience from Türkiye.Clinical rheumatology · 2025Observational
- Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study.BMC rheumatology · 2025Article
- Efficacy and Safety of Anakinra in Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Single-Center Real-Life Experience.Medicina (Kaunas, Lithuania) · 2025Article
- Familial Mediterranean Fever Intertwined With a Diagnosis of Crohn's Disease: A Case Report.Cureus · 2025Article
- Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review.Reumatologia · 2025Review
- Idiopathic AA amyloidosis presenting with initial abdominal pain: a case report and literature review.Frontiers in medicine · 2025Article
- Familial Mediterranean Fever in Childhood.Turkish archives of pediatrics · 2024Review
- The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever.Clinical rheumatology · 2024Article
- Recent Insights in Pyrin Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin-Associated Autoinflammatory Syndromes.Journal of clinical immunology · 2023Review
- Does switching from coated colchicine to compressed colchicine improves treatment response in patients with familial Mediterranean fever?Croatian medical journal · 2023Article
- An Update on Familial Mediterranean Fever.International journal of molecular sciences · 2023Review
- Tocilizumab for the Treatment of Familial Mediterranean Fever-A Randomized, Double-Blind, Placebo-Controlled Phase II Study.Journal of clinical medicine · 2022Article
- Article
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo.EMBO molecular medicine · 2022Article
- [What is confirmed in the treatment of autoinflammatory fever diseases?]Der Internist · 2021Review
- Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases.Frontiers in pediatrics · 2021Article
- Gut Microbiota between Environment and Genetic Background in Familial Mediterranean Fever (FMF).Genes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn 5%-10% of patients with familial Mediterranean fever (FMF), colchicine is not effective in preventing inflammatory attacks. Another 5%-10% of patients are intolerant to effective doses of colchicine and experience serious side effects. Treatment with anti-interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed for this indication in many countries.
methodsWe systematically searched PubMed, Web of Science, and Scopus for reports of anti-IL-1 treatment in FMF patients.
resultsOut of 284 potentially relevant articles, 27 eligible reports were identified and included in the data analysis.
conclusionA complete response to therapy without a single attack during treatment was reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canakinumab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients with FMF who do not respond to or cannot tolerate colchicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.